US Patent

US12138264 — Pharmaceutical compositions

Method of Use · Assigned to ViiV Healthcare Co · Expires 2031-09-15 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions of a specific compound useful in treating or preventing HIV infections.

USPTO Abstract

The present Invention relates to pharmaceutical compositions of (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.

Drugs covered by this patent

Vocabria (CABOTEGRAVIR) · GSK

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3348`	—	Vocabria
`U-3348`	—	Vocabria

Patent Metadata

Patent number: US12138264
Jurisdiction: US
Classification: Method of Use
Expires: 2031-09-15
Drug substance claim: No
Drug product claim: Yes
Assignee: ViiV Healthcare Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.